Research Paper Volume 16, Issue 10 pp 9047—9071
Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma
Figure 6. Evaluating the predictive capability of the programmed cell death index for drug sensitivity. (A) The correlation between the drug IC50 and PCD genes in model. (B) The correlation between the IC50 of drugs and PCDI values in patients with high- or low-PCDI, highlighting enhanced sensitivity to standard adjuvant chemotherapy in low PCDI LIHC patients. (C) The association between model genes and established targets for the treatment of LIHC.